In our study, specific analysis of publicly available prostate tumors and normal tissue-specific AR-binding sites (ARBSs) revealed that among the 85 DEGs, 47 had at least one tumor-specific AR-binding site within their regulatory regions. This evidence concerns the gene AR and prostate neoplasm.